These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.
    Author: Michel M, Duvoux C, Hezode C, Cherqui D.
    Journal: J Rheumatol; 2003 Jul; 30(7):1624-5. PubMed ID: 12858469.
    Abstract:
    Infliximab, a chimeric anti-tumor necrosis factor-alpha monoclonal antibody, has been demonstrated to be efficient and safe in patients with active rheumatoid arthritis and in the management of severe bouts of Crohn's disease. However, the safety of infliximab has not been evaluated in patients infected with hepatitis B virus. We report the case of a 28-year-old woman, with a positive hepatitis B virus surface antigen, who developed fulminant hepatitis 2 weeks after receiving a second infliximab infusion for a refractory adult onset Still's disease.
    [Abstract] [Full Text] [Related] [New Search]